|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 3/02/20 Evolent Health, Inc. 10-K 12/31/19 150:20M |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 2.78M
2: EX-4.8 Instrument Defining the Rights of Security Holders HTML 64K
3: EX-21.1 Subsidiaries List HTML 42K
4: EX-23.1 Consent of Experts or Counsel HTML 40K
5: EX-23.2 Consent of Experts or Counsel HTML 40K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 48K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 48K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 42K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 42K
133: R1 Cover Page HTML 105K
79: R2 Consolidated Balance Sheets HTML 162K
30: R3 Consolidated Balance Sheets (Parenthetical) HTML 52K
112: R4 Consolidated Statements of Operations and HTML 138K
Comprehensive Income (Loss)
134: R5 Consolidated Statements of Changes in HTML 144K
Shareholders' Equity (Deficit)
80: R6 Consolidated Statements of Cash Flows HTML 166K
31: R7 Organization HTML 48K
115: R8 Basis of Presentation, Summary of Significant HTML 149K
Accounting Policies and Change in Accounting
Principle
132: R9 Recently Issued Accounting Standards HTML 51K
136: R10 Transactions HTML 155K
84: R11 Revenue Recognition HTML 94K
38: R12 Property and Equipment, Net HTML 58K
55: R13 Goodwill and Intangible Assets, Net HTML 127K
137: R14 Long-term Debt HTML 97K
85: R15 Commitments and Contingencies HTML 108K
39: R16 Leases HTML 80K
56: R17 Earnings (Loss) Per Common Share HTML 76K
135: R18 Stock-based Compensation HTML 186K
86: R19 Income Taxes HTML 202K
28: R20 Employee Benefit Plans HTML 43K
82: R21 Investments In and Advances to Equity Method HTML 97K
Investees
130: R22 Non-controlling Interests HTML 73K
113: R23 Fair Value Measurement HTML 168K
29: R24 Related Parties HTML 76K
83: R25 Segment Reporting HTML 173K
131: R26 Reserves for Claims and performance-Based HTML 98K
Arrangements
114: R27 Investments HTML 105K
33: R28 Quarterly Results of Operations (Unaudited) HTML 93K
81: R29 Supplemental Cash Flow Information HTML 83K
53: R30 Basis of Presentation, Summary of Significant HTML 245K
Accounting Policies and Change in Accounting
Principle (Policies)
37: R31 Basis of Presentation, Summary of Significant HTML 140K
Accounting Policies and Change in Accounting
Principle (Tables)
88: R32 Transactions (Tables) HTML 90K
139: R33 Revenue Recognition (Tables) HTML 74K
52: R34 Property and Equipment, Net (Tables) HTML 58K
36: R35 Goodwill and Intangible Assets, Net (Tables) HTML 120K
87: R36 Long-term Debt (Tables) HTML 58K
138: R37 Commitments and Contingencies (Tables) HTML 78K
54: R38 Leases (Tables) HTML 75K
34: R39 Earnings (Loss) Per Common Share (Tables) HTML 79K
75: R40 Stock-based Compensation (Tables) HTML 167K
27: R41 Income Taxes (Tables) HTML 192K
100: R42 Investments In and Advances to Equity Method HTML 90K
Investees Investments In and Advances to Equity
Method Investees (Tables)
120: R43 Non-controlling Interests (Tables) HTML 55K
73: R44 Fair Value Measurement (Tables) HTML 219K
25: R45 Related Parties (Tables) HTML 71K
99: R46 Segment Reporting (Tables) HTML 170K
118: R47 Reserves for Claims and performance-Based HTML 91K
Arrangements (Tables)
76: R48 Investments (Tables) HTML 106K
22: R49 Quarterly Results of Operations (Unaudited) HTML 93K
(Tables)
46: R50 Supplemental Cash Flow Information (Tables) HTML 82K
65: R51 Organization (Details) HTML 45K
140: R52 Basis of Presentation, Summary of Significant HTML 41K
Accounting Policies and Change in Accounting
Principle - Operating Segments (Details)
91: R53 Basis of Presentation, Summary of Significant HTML 89K
Accounting Policies and Change in Accounting
Principle - Restricted Cash and Restricted
Investments (Details)
48: R54 Basis of Presentation, Summary of Significant HTML 57K
Accounting Policies and Change in Accounting
Principle - Notes Receivable (Details)
66: R55 Basis of Presentation, Summary of Significant HTML 52K
Accounting Policies and Change in Accounting
Principle - Estimated Useful Life of Property,
Plant and Equipment (Details)
141: R56 Basis of Presentation, Summary of Significant HTML 44K
Accounting Policies and Change in Accounting
Principle - Research and Development Costs
(Details)
92: R57 Basis of Presentation, Summary of Significant HTML 42K
Accounting Policies and Change in Accounting
Principle - Goodwill (Details)
50: R58 Basis of Presentation, Summary of Significant HTML 53K
Accounting Policies and Change in Accounting
Principle - Intangible Assets, Net (Details)
62: R59 Basis of Presentation, Summary of Significant HTML 43K
Accounting Policies and Change in Accounting
Principle - Impairment of Equity Method
Investments (Details)
126: R60 Basis of Presentation, Summary of Significant HTML 45K
Accounting Policies and Change in Accounting
Principle - Revenue Recognition (Details)
104: R61 Basis of Presentation, Summary of Significant HTML 45K
Accounting Policies and Change in Accounting
Principle - Stock-based Compensation (Details)
18: R62 Recently Issued Accounting Standards (Details) HTML 47K
67: R63 Transactions - Passport (Details) HTML 71K
129: R64 Transactions - New Century Health (Details) HTML 144K
107: R65 Transactions - New Mexico Health Connections HTML 83K
(Details)
21: R66 Transactions - Pro Forma Information (Unaudited) HTML 55K
(Details)
70: R67 Transactions - Securities Offerings and Sales HTML 143K
(Details)
122: R68 Transactions - Asset Acquisitions (Details) HTML 53K
109: R69 Revenue Recognition - Disaggregation of Revenue HTML 59K
(Details)
98: R70 Revenue Recognition - Transaction Price Allocated HTML 45K
to the Remaining Performance Obligations (Details)
147: R71 Revenue Recognition - Contract Balances (Details) HTML 80K
60: R72 Revenue Recognition - Contract Costs (Details) HTML 52K
44: R73 Property and Equipment, Net (Details) HTML 68K
95: R74 Goodwill and Intangible Assets, Net - Impairment HTML 59K
Testing (Details)
144: R75 Goodwill and Intangible Assets, Net - Schedule of HTML 63K
Goodwill (Details)
57: R76 Goodwill and Intangible Assets, Net - Intangible HTML 71K
Assets, Net (Details)
41: R77 Goodwill and Intangible Assets, Net - Amortization HTML 57K
of Intangible Assets (Details)
94: R78 Long-term Debt - Credit Agreement (Details) HTML 84K
149: R79 Long-term Debt - Warrant Agreement (Details) HTML 47K
97: R80 Long-term Debt - 2025 Notes (Details) HTML 92K
146: R81 Long-term Debt - 2021 Notes (Details) HTML 78K
59: R82 Long-term Debt - Convertible Senior Notes Carrying HTML 73K
Value (Details)
43: R83 Commitments and Contingencies - Additional HTML 95K
Information (Details)
96: R84 Commitments and Contingencies - Purchase HTML 49K
Obligations (Details)
145: R85 Commitments and Contingencies - Reinsurance HTML 54K
Agreements (Details)
58: R86 Commitments and Contingencies - Concentration Risk HTML 65K
(Details)
42: R87 Leases - Narratives (Details) HTML 51K
93: R88 Leases - Material Office Leases (Details) HTML 63K
148: R89 Leases - Components of Lease Expense (Details) HTML 52K
127: R90 Leases - Maturity of Lease Liabilities (Details) HTML 62K
105: R91 Leases - Weighted-average Discount Rate and HTML 44K
Weighted-remaining Lease Terms (Details)
19: R92 Earnings (Loss) Per Common Share - Computation of HTML 74K
Earnings per Share (Details)
68: R93 Earnings (Loss) Per Common Share - Antidilutive HTML 54K
Securities (Details)
128: R94 Stock-based Compensation - 2011 and 2015 Equity HTML 64K
Incentive Plans (Details)
106: R95 Stock-based Compensation - Stock-based HTML 63K
Compensation Expense (Details)
20: R96 Stock-based Compensation - Unrecognized HTML 59K
Compensation Expense (Details)
69: R97 Stock-based Compensation - Stock Options (Details) HTML 74K
124: R98 Stock-based Compensation - Stock Option Activity HTML 95K
(Details)
111: R99 Stock-based Compensation - Performance-based Stock HTML 115K
Option Awards (Details)
23: R100 Stock-based Compensation - Restricted Stock Units HTML 85K
(Details)
77: R101 Stock-based Compensation - Leveraged Stock Units HTML 75K
(Details)
116: R102 Stock-based Compensation - Leveraged Stock Units HTML 62K
Activity (Details)
101: R103 Stock-based Compensation - Performance-based RSUs HTML 65K
(Details)
24: R104 Income Taxes - Narrative (Details) HTML 95K
78: R105 Income Taxes - Schedule of Loss Before Provision HTML 48K
for Income Taxes (Details)
117: R106 Income Taxes - Income Tax Expense (Benefit) HTML 75K
(Details)
102: R107 Income Taxes - Reconciliation of Statutory Rate to HTML 86K
Effective Tax Rate (Details)
26: R108 Income Taxes - Deferred Tax Assets and Liabilities HTML 105K
(Details)
74: R109 Income Taxes - Changes in Valuation Allowance HTML 51K
(Details)
63: R110 Income Taxes - Changes In Unrecognized Tax HTML 56K
Benefits (Details)
51: R111 Employee Benefit Plans (Details) HTML 42K
90: R112 Investments In and Advances to Equity Method HTML 87K
Investees (Details)
143: R113 Investments In and Advances to Equity Method HTML 75K
Investees - Schedule of Assets and Liabilities and
Maximum Loss Exposure of Unconsolidated VIEs
(Details)
61: R114 Investments In and Advances to Affiliates - HTML 77K
Summarized Financial Information (Details)
49: R115 Non-controlling Interests (Details) HTML 155K
89: R116 Fair Value Measurement - Assets and Liabilities on HTML 84K
Recurring Basis (Details)
142: R117 Fair Value Measurement (Details) HTML 50K
64: R118 Fair Value Measurement - Changes in Contingent HTML 51K
Consideration and Other (Details)
45: R119 Fair Value Measurement - Valuation Techniques and HTML 100K
Significant Unobservable Inputs (Details)
110: R120 Related Parties (Details) HTML 45K
123: R121 Related Parties - Assets and Liabilities (Details) HTML 68K
72: R122 Related Parties - Revenues and Expenses (Details) HTML 68K
17: R123 Segment Reporting (Details) HTML 109K
108: R124 Segment Reporting - Reconciliation of Adjusted HTML 98K
EBITDA (Details)
121: R125 Reserves for Claims and performance-Based HTML 70K
Arrangements - Claims Reserves (Details)
71: R126 Investments - Investment Summary (Details) HTML 63K
15: R127 Investments - Contractual Maturity (Details) HTML 66K
103: R128 Investments - Unrealized Losses (Details) HTML 49K
125: R129 Quarterly Results of Operations (Unaudited) HTML 68K
(Details)
150: R130 Supplemental Cash Flow Information (Details) HTML 94K
47: R9999 Uncategorized Items - evh12311910-k.htm HTML 42K
40: XML IDEA XML File -- Filing Summary XML 285K
32: XML XBRL Instance -- evh12311910-k_htm XML 5.24M
119: EXCEL IDEA Workbook of Financial Reports XLSX 198K
11: EX-101.CAL XBRL Calculations -- evh-20191231_cal XML 432K
12: EX-101.DEF XBRL Definitions -- evh-20191231_def XML 1.64M
13: EX-101.LAB XBRL Labels -- evh-20191231_lab XML 3.24M
14: EX-101.PRE XBRL Presentations -- evh-20191231_pre XML 2.23M
10: EX-101.SCH XBRL Schema -- evh-20191231 XSD 330K
16: JSON XBRL Instance as JSON Data -- MetaLinks 667± 1.06M
35: ZIP XBRL Zipped Folder -- 0001628908-20-000032-xbrl Zip 748K
| Exhibit |
1. | I have reviewed this Annual Report on Form 10-K of Evolent Health, Inc.; |
2. | Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including
its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the
registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Dated: | /s/ John Johnson | ||
Name: John
Johnson | |||
Title: Chief Financial Officer | |||
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/2/20 | 4 | ||
| For Period end: | 12/31/19 | 8-K | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/15/21 Evolent Health, Inc. S-8 6/15/21 4:87K 2/26/21 Evolent Health, Inc. 10-K 12/31/20 152:19M |